HOME >> BIOLOGY >> NEWS
Resistance and genetic sensitivity to sleeping sickness

Human African trypanosomiasis, more commonly called sleeping sickness, is induced by a parasite, the trypanosome, transmitted to humans by the bite of an insect, the glossinid tse-tse fly. There has been a resurgence of this disease over the past 20 years in Sub-Saharan Africa. The World Health Organization (WHO) in a 1998 report estimated the number of people infected to be about 300 000. Awareness of the seriousness of the situation led to an increase in screening and treatment operations over the past five years, allowing a substantial fall in the number of subjects infected.

Sleeping sickness classically manifests itself in two forms, corresponding to two parasite subspecies. The chronic form, encountered in Central and West African countries, is caused by Trypanosoma brucei gambiense (T.b. gambiense). Its development cycle in the host vaires greatly, from a few months to several years. The acute form of the disease is brought on by Trypanosoma brucei rhodesiense (T.b. rhodesiense), in southern and eastern African countries. The infection it induces takes effect after a few weeks. More virulent than the chronic form, its development cycle is also more rapid and, consequently, clinical detection can be made earlier.

However, it is increasingly recognized that the existence of these two forms, the chronic one due to T. b. gambiense and the acute one provoked by T. b. rhodesiense, only partly reflect the real mechanisms at work. Concerning the Gambian form, the screening and treatment teams indicates the occurrence of several categories of subjects infected: some show Glossina fuscipes gorged with blood affected by classical chronic forms of the disease; others bear severe rapidly developing forms; still other people show no symptoms of human African trypanosomiasis, in spite of a long period of infection. This diversity in host clinical presentation in reaction to infection can have several sources: the host's ability to respond to infection
'"/>

Contact: Marie Guillaume-Signoret
guillaum@paris.ird.fr
33-014-803-7607
Institut de Recherche Pour le Dveloppement
13-Oct-2006


Page: 1 2 3

Related biology news :

1. Resistance genes in our food supply
2. Resistance to chemotherapy in lung cancer, optimizing flu vaccination strategies
3. Resistance training benefits older Hispanic adults with type 2 diabetes
4. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
5. Does the desire to consume alcohol and tobacco come from our genetic makeup?
6. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
7. Penn researchers discover pathway that eliminates genetic defects in red blood cells
8. Identifying the mechanism behind a genetic susceptibility to type 2 diabetes
9. After a decades-long search, scientists identify new genetic risk factors for multiple sclerosis
10. Discoverer of Sly Syndrome finds way of delivering medicine to fight rare genetic disorder
11. Identified main genetic variants involved in response to HIV

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/9/2019)... (PRWEB) , ... March 07, 2019 , ... A firm ... to The Leukemia & Lymphoma Society (LLS). This donation will help fund not only ... patients and their families. , “We are always on the lookout for ways ...
(Date:3/9/2019)... ... March 09, 2019 , ... ... hM4Di ligands – exciting compounds for scientists studying GPCR and DREADD signalling. Hello ... and the National Institute of Neurological Disorders and Stroke, both institutes of the ...
(Date:2/27/2019)... ... 2019 , ... Fluxion Biosciences, a leading developer of precision solutions for life ... grant for further development of its ERASE-Seq liquid biopsy technology. The Phase I grant ... Dr. Omar Mian at the Cleveland Clinic. , Liquid biopsies offer the potential to ...
Breaking Biology News(10 mins):
(Date:3/14/2019)... ... March 14, 2019 , ... ... solution for preclinical research organizations. It is a low code, GDPR/21 CFR ... and facilities, innovative technology-driven automated data capture and seamless data and information ...
(Date:3/11/2019)... ... , ... USDM Life Sciences and Generis have partnered ... GxP compliance for the life sciences industry. USDM Cloud Assurance delivers a ... for Generis’ flagship product, CARA. , Presentation One:, What: Cloud ...
(Date:3/5/2019)... ... March 05, 2019 , ... Modality Solutions, ... with regulatory filing authorities, logistics network experts, and experienced integrated staffing professionals. ... in the Inc. Verified Profile program, Inc. editors independently reviewed the Houston-based cold ...
(Date:2/26/2019)... ... February 26, 2019 , ... The idea for ... Villani developed the Visikol® tissue clearing technology for improved tissue characterization. From this ... products focused company to primarily a services focused company. , Today, Visikol ...
Breaking Biology Technology:
Cached News: